{"title":"钠-葡萄糖共转运体 2 型 (SGLT2) 抑制剂在治疗 2 型糖尿病方面面临的挑战:疗效与感染风险并存","authors":"Anne-Cécile Ezanno , Pierre-Louis Conan , Cyril Garcia","doi":"10.1016/j.jchirv.2023.12.002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73567,"journal":{"name":"Journal de chirurgie viscerale","volume":"161 3","pages":"Pages 175-176"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Le défi des inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2) dans le traitement du diabète de type 2 : entre efficacité et risques infectieux\",\"authors\":\"Anne-Cécile Ezanno , Pierre-Louis Conan , Cyril Garcia\",\"doi\":\"10.1016/j.jchirv.2023.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73567,\"journal\":{\"name\":\"Journal de chirurgie viscerale\",\"volume\":\"161 3\",\"pages\":\"Pages 175-176\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal de chirurgie viscerale\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1878786X24000019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de chirurgie viscerale","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878786X24000019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Le défi des inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2) dans le traitement du diabète de type 2 : entre efficacité et risques infectieux